In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Histrelin | Synthetic analog Triptorelin (Trelstar, Decapeptyl) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 246 | 1,338 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 48 (48 in people) | 164 (160 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 11 · 5 active3 more mention it but do not test it | 207 · 44 active104 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Supprelin LA says: “Children with central precocious puberty, using the Supprelin LA histrelin acetate subcutaneous implant”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Histrelin | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 1559560 | 782599171 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Trelstar says: “Treatment of advanced prostate cancer”
| Adverse eventsWhole body | 4040 | 105105 |
|---|
| Bone and jointMusculoskeletal | 66 | 74713 |
|---|
| Linear growthMusculoskeletal | 99 | 6767 |
|---|
| Tumor growthCancer | 1212 | 524624 |
|---|
| Receptor activity and mechanismEndocrine and hormones | 422 | 7425715 |
|---|
| PharmacokineticsPharmacology | 33 | 19136 |
|---|
| Body weightMetabolic and weight | 11 | 17161 |
|---|
| MortalityWhole body | 22 | 1212 |
|---|
| Patient-reported outcomesWhole body | 11 | 44 |
|---|
| Liver fat and liver functionLiver | 11 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Histrelin differs from Gonadorelin at 2 positions.
What is different
Triptorelin (Trelstar, Decapeptyl) differs from Gonadorelin at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Histrelin | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | No randomized trial result 155 results from other study designs. | 22.7% Pregnancy rate Placebo: 22.1% Dose studied: 0.1 mgSingle injectionn = 3442010 |
| MortalityCancerCompared as: value in the arm that got the peptide, in % | No randomized trial result 2 results from other study designs. | 97% Survival Dose studied: 3.75 mg9 monthsn = 2842003 |
| Tumor growthCancerCompared as: value in the arm that got the peptide, in months | No randomized trial result 12 results from other study designs. | 39.1 months 25th percentile BRFS Dose studied: 11.25 mg at baseline and at 3 and 6 months9 monthsn = 2262024 |
| Linear growthEndocrine and hormonesCompared as: value in the arm that got the peptide, in years | No randomized trial result 9 results from other study designs. | 11.9 years Age at menarche Dose studied: 3.75 mg every four weeksn not reported1999 |
| Adverse eventsReproductive and sexual healthCompared as: difference from placebo, in percentage points | No randomized trial result 40 results from other study designs. | −14.7 percentage points Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size. Dose studied: 0.1 mg, single dosen = 1442018 |
| Bone and jointEndocrine and hormonesCompared as: value in the arm that got the peptide, in nmol/l | No randomized trial result 6 results from other study designs. | 0.49 nmol/L Serum osteocalcin Dose studied: 3.75 mg every 28 days6 monthsn = 101994 |
No randomized trial result
155 results from other study designs.
22.7%
Pregnancy rate
Placebo: 22.1%
Dose studied: 0.1 mgSingle injectionn = 3442010
No randomized trial result
2 results from other study designs.
97%
Survival
Dose studied: 3.75 mg9 monthsn = 2842003
No randomized trial result
12 results from other study designs.
39.1 months
25th percentile BRFS
Dose studied: 11.25 mg at baseline and at 3 and 6 months9 monthsn = 2262024
No randomized trial result
9 results from other study designs.
11.9 years
Age at menarche
Dose studied: 3.75 mg every four weeksn not reported1999
No randomized trial result
40 results from other study designs.
−14.7 percentage points
Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size.
Dose studied: 0.1 mg, single dosen = 1442018
No randomized trial result
6 results from other study designs.
0.49 nmol/L
Serum osteocalcin
Dose studied: 3.75 mg every 28 days6 monthsn = 101994
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 11 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Endo USA Inc., a Keenova Therapeutics Company36 participantsSept 2004 to Apr 2012
Central Precocious Puberty
NRG Oncology2,753 participants21 Jan 2021 to est. 31 Dec 2038
Prostate Adenocarcinoma · Stage III Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8
NRG Oncology2,050 participants6 Dec 2021 to est. 11 Nov 2031
Prostate Adenocarcinoma
3 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma · Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer · Stage IIB Breast Cancer · Stage IIIA Breast Cancer
ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024
Breast Cancer
Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)
Prostate Cancer
104 more mention it but do not test it. They only measure it or name it in their text.